Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.72 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11884643 | 0.88 | ADRB2 (0.80) | KMT2AADRB2ADRB1ADRB3HTR1A | |
| SCHEMBL7116296 | 0.87 | ADRB3 (0.79) | KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL10555388 | 0.87 | KMT2A (0.75) | KMT2AADRB2ADRB1HTR1AADRA2C | |
| SCHEMBL11259043 | 0.87 | KMT2A (0.75) | KMT2AADRB2ADRB1HTR1AADRA2C | |
| SCHEMBL10554140 | 0.87 | KMT2A (0.75) | KMT2AADRB2ADRB1HTR1AADRA2C | |
| SCHEMBL22279157 | 0.85 | ADRB3 (0.79) | KMT2AADRB2ADRB1ADRB3HTR1A | |
| SCHEMBL29900715 | 0.85 | ADRB3 (0.79) | KMT2AADRB2ADRB1ADRB3HTR1A | |
| SCHEMBL5963374 | 0.85 | KMT2A (0.72) | KMT2AADRB2ADRB1HTR1AADRA2C | |
| SCHEMBL4531206 | 0.85 | KMT2A (0.72) | KMT2AADRB2ADRB1HTR1AADRA2C | |
| SCHEMBL8790970 | 0.84 | KMT2A (0.71) | KMT2AADRB2ADRB1HTR1AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |